Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-dose, Pharmacokinetic Study to Evaluate IV Eptinezumab in Children and Adolescents With Migraine, Followed by an Optional, Multiple-dose, Open-label Extension Period

NCT04537429 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT04537429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04537429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-dose, Pharmacokinetic Study to Evaluate IV Eptinezumab in Children and Adolescents With Migraine, Followed by an Optional, Multiple-dose, Open-label Extension Period
Lead sponsor
H. Lundbeck A/S
Phase
Phase 1
Overall status
Completed
Start date
August 4, 2020
Completion date
August 21, 2023
Enrollment
28 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

migraine, migraine in children